Yesh V. Dhruva

Yesh V. Dhruva

Auto-generated profile, based on publicly available information

Yesh V. Dhruva

Saint Louis University School of Medicine, St. Louis, MO, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2026 in Heart & Lung
Verified
Journal Article
Open access
YDYesh V Dhruva
Yesh V Dhruva
AKAkhil V Kumar
Akhil V Kumar
ASAtman K Shah
Atman K Shah
RPRohit B Ponnada
Rohit B Ponnada
NMNicholas Mootz
Nicholas Mootz
CLChien-Jung Lin
Chien-Jung Lin
Coronary stent restenosis remains a clinically significant challenge, often resulting in recurrent myocardial infarction (MI). Optimal antiplatelet therapy following restenosis is unclear, as most comparative studies were conducted in broader acute coronary syndrome populations. We conducted a retrospective cohort study using TriNetX to identify patients with in-stent restenosis (ICD-10: T82.855) who were subsequently prescribed clopidogrel, prasugrel, or ticagrelor. The primary outcome was acute MI (ICD-10: I21) within one year of prescription. Adjusted Cox proportional hazards models compared MI risk between agents, controlling for age, sex, HbA1c, heart failure, CKD, cerebrovascular disease, and mortality. Among 40,206 patients, MI occurred in 22.5% of prasugrel users (n=1,139), 29.0% of clopidogrel users (n=35,071), and 35.9% of ticagrelor users (n=4,041). Compared to clopidogrel, ticagrelor was associated with significantly increased MI risk (HR 1.552; 95% CI: 1.467-1.642; p<0.001), while prasugrel showed no significant difference (HR 0.94; 95% CI: 0.835-1.057; p=0.3). Prasugrel was associated with significantly lower risk compared to ticagrelor (HR 0.589; 95% CI: 0.519-0.669; p<0.001). In this real-world cohort of patients with coronary stent restenosis, ticagrelor was associated with a significantly higher 1-year MI risk compared to clopidogrel and prasugrel. These findings suggest potential differences in clinical outcomes among P2Y12 inhibitors in this high-risk setting and highlight the need for further prospective investigation to confirm these results.

11 November 2025 in American Journal of Therapeutics
Verified
Journal Article
Closed access
YDYesh V. Dhruva
Yesh V. Dhruva
RPRohit B. Ponnada
Rohit B. Ponnada
AKAkhil V. Kumar
Akhil V. Kumar
ASAtman K. Shah
Atman K. Shah
CLChien-Jung Lin
Chien-Jung Lin

26 February 2026 in Health Science Reports
Verified
Journal Article
Open access
RPRohit B. Ponnada
Rohit B. Ponnada
YDYesh V. Dhruva
Yesh V. Dhruva
AKAkhil V. Kumar
Akhil V. Kumar
NMNicholas Mootz
Nicholas Mootz
VPVenkata Praneeth Peddada
Venkata Praneeth Peddada
CLChien-Jung Lin
Chien-Jung Lin
Background and Aims: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with increasing recognition of cardiovascular disease (CVD) as a major contributor to mortality. National data on cardiovascular deaths among individuals with IPF remains limited, and the impact of various disparities is unclear. The purpose of this study was to examine trends in the United States mortality rate involving cardiovascular deaths and pre‐existing pulmonary fibrosis. Methods: This was a retrospective cohort study conducted by gathering mortality data from the Centers for Disease Control and Prevention's Wide‐Ranging Online Data for Epidemiologic Research (CDC WONDER) publicly available database between the years 1999 and 2020. Death certificate data was extrapolated in this database, from which the subset of pulmonary fibrosis patients (ICD‐10 J84.1) were analyzed for cardiovascular‐related deaths (I00‐I99). Statistical analysis was then conducted via the Joinpoint regression software. Results: There were 47,814 cardiovascular‐related deaths with underlying pulmonary fibrosis between 1999 and 2000. The overall age‐adjusted mortality rate (AAMR) per 100,000 increased from 59.1 in 1999 to 134.5 in 2020 (Annual percent change [APC] = 3.37%, p < 10⁻⁶). Males had a higher AAMR and more pronounced increase than females (APC male  = 4.09%, p < 10⁻⁶; APC female = 1.63%, p = 0.056). White individuals had the highest AAMR with the steeper upward mortality trend. Conclusions: Cardiovascular deaths with underlying pulmonary fibrosis have consistently increased from 1999 to 2020, highlighting the urgent need for preventative techniques and the necessity for additional targeted public health interventions based on demographic disparities.

17 March 2026 in American Journal of Therapeutics
Verified
Journal Article
Closed access
YDYesh Dhruva
Yesh Dhruva
RPRohit B. Ponnada
Rohit B. Ponnada
BPBhanuteja Pujari
Bhanuteja Pujari
RGRushil Gupta
Rushil Gupta
CLChing-Hsien Lu
Ching-Hsien Lu
CLChien-Jung Lin
Chien-Jung Lin